<DOC>
	<DOCNO>NCT03014089</DOCNO>
	<brief_summary>The clinical study ass safety , tolerability , immunogenicity mRNA-1325 healthy adult subject .</brief_summary>
	<brief_title>Safety , Tolerability , Immunogenicity mRNA-1325 Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion 18 49 year age Body mass index 18 35 kg/m2 In good health determine medical history Female subject must non pregnant non lactate meet one follow criterion : ) post menopausal b ) surgically sterile Women childbearing potential must agree heterosexually inactive agree consistently use follow method contraception least 21 day prior enrollment 3 month final vaccination Male subject must use acceptable method birth control throughout entire study agree refrain donation sperm time first vaccination 3 month follow last vaccination Agrees comply study procedure provide write informed consent Has access consistent reliable mean telephone contact agree stay contact study site duration study , provide update contact information necessary , current plan move study area duration study Exclusion Any ongoing , symptomatic acute chronic illness require medical surgical care A history active cancer ( malignancy ) last 10 year Female childbearing potential positive pregnancy test screen day vaccination Administration investigational product within 60 day , 5 halflives , whichever long Administration live attenuate vaccine within 4 week enrollment inactive vaccine within 2 week enrollment , plan receive vaccine active vaccination period Prior administration vaccine Zika dengue vaccine , history confirm Zika dengue infection , live visited Zikaendemic area great 4 week duration Prior administration investigational agent use formulation similar mRNA1325 A history hypersensitivity serious reaction previous vaccination Any know suspected autoimmune disease immunosuppressive condition , acquire congenital , determined medical history and/or physical examination A history inflammatory arthritis Any neurologic disorder A history febrile disease arthritis arthralgia within 2 week dose administration . Prior administration immunoglobulins and/or blood product within 3 month precede administration study drug plan receive product time study Any chronic administration immunosuppressant immune modify drug Any acute illness time enrollment Any significant disorder coagulation require ongoing intermittent treatment A history idiopathic urticaria A history alcohol abuse drug addiction A positive test result drug abuse The subject abnormality permanent body art ( eg , tattoo ) , opinion investigator , would obstruct ability observe local reaction injection site Any condition , opinion investigator , would pose health risk subject enrol could interfere evaluation study drug interpretation study result A positive test result hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus type 1 2 antibody Donation blood blood product &gt; 450 mL within 30 day dose . Abnormal vital sign screen safety laboratory test result include liver enzyme test Is employee first degree relative Sponsor , CRO , study site personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mRNA-1325</keyword>
	<keyword>Zika vaccine</keyword>
</DOC>